IP Library Granted Patent US 9,504,719
Granted Patent B2
US 9,504,719 · App. 11/316,104 · Granted Nov 29, 2016

Soft tissue repair and regeneration using postpartum-derived cells and cell products

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,504,719
App. No.
11/316,104
Granted
Nov 29, 2016
Kind
B2
Abstract

Cells derived from postpartum tissue and products thereof having the potential to support cells of and/or differentiate to cells of a soft tissue lineage, and methods of preparation and use of those postpartum tissue-derived cells, are provided by the invention. The invention also provides methods for the use of such postpartum-derived cells and products related thereto in therapies for conditions of soft tissue.

Claims (34)

1. A method of making a cell lysate comprising lysing cells of a homogeneous umbilical cord cell population isolated from human umbilical cord tissue substantially free of blood, wherein said cell population self-renews and expands in culture, provides trophic support to a soft tissue cell, and has the following characteristics:

a) secretes MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, RANTES, and TIMP1;

b) production of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;

c) lacks production of CD31, CD34, CD45, CD80, CD86, CD 117, CD141, CD178, B7-H2, HLA-G, and HLA-DR,DP,DQ;

d) has increased expression, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, of interleukin 8, reticulon 1 and chemokine (C-X-C motif) ligand 3; and

e) has the ability to undergo at least 40 population doublings in culture,

wherein a cell lysate is produced.

2. The method of claim 1 further comprising adding one or more bioactive factors.

3. The method of claim 2 wherein said bioactive factor is at least one of a differentiation-inducing factor, an anti-apoptotic agent, an anti-inflammatory agent, an immunosupressive/immunomodulatory agent, an anti-proliferative agent, a corticosteroid, an antibody, an anti-thrombogenic agent, an anti-oxidant, and scar inhibitory factor.

4. The method of claim 1 , further comprising adding a pharmaceutically acceptable carrier.

5. The method of claim 1 , wherein said cell population lacks secretion of SDF-1alpha, TGF-beta2, ANG2, PDGFbb, MIP1a, and VEGF.

6. The method of claim 1 , further comprising lyophilizing the cell lysate.

7. The method of claim 1 , wherein the cell lysing comprises disrupting the cells using freeze-thaw disruption, osmotic disruption, mechanical disruption, ultrasonic disruption, enzymatic disruption or chemical disruption.

8. A method of making a lyophilized cell lysate comprising lysing cells of a homogeneous umbilical cord cell population isolated from human umbilical cord tissue substantially free of blood, wherein said cell population self-renews and expands in culture, provides trophic support to a soft tissue cell, and has the following characteristics:

a) secretes MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, RANTES, and TIMP1;

b) production of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;

c) lacks production of CD31, CD34, CD45, CD80, CD86, CD 117, CD141, CD178, B7-H2, HLA-G, and HLA-DR,DP,DQ;

d) has increased expression, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, of interleukin 8, reticulon 1 and chemokine (C-X-C motif) ligand 3; and

e) has the ability to undergo at least 40 population doublings in culture

wherein a cell lysate is produced, and

lyophilizing the cell lysate.

9. The method of claim 8 , wherein said cell population lacks secretion of SDF-1alpha, TGF-beta2, ANG2, PDGFbb, MIP1a, and VEGF.

10. The method of claim 8 , wherein the lysate comprises HGF, FGF, IL-8, TIMP1 and BDNF.

11. The method of claim 10 , wherein the lysate further comprises ANG2, HB-EGF, KGF, PDGFbb, VEGF, IL-6, MCP1 TGFa, TIMP2, and HGH.

12. The method of claim 8 further comprising adding one or more bioactive factors.

13. The method of claim 12 , wherein said bioactive factor is at least one of a differentiation-inducing factor, an anti-apoptotic agent, an anti-inflammatory agent, an immunosupressive/immunomodulatory agent, an anti-proliferative agent, a corticosteroid, an antibody, an anti-thrombogenic agent, an anti-oxidant, and scar inhibitory factor.

14. A method of making a cell lysate matrix complex comprising lysing cells of a homogeneous umbilical cord cell population isolated from human umbilical cord tissue substantially free of blood, wherein said cell population self-renews and expands in culture, provides trophic support to a soft tissue cell, and has the following characteristics:

a) secretes MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, RANTES, and TIMP1;

b) production of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;

c) lacks production of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DR,DP,DQ;

d) has increased expression, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, of interleukin 8, reticulon 1 and chemokine (C-X-C motif) ligand 3; and

e) has the ability to undergo at least 40 population doublings in culture;

wherein a cell lysate is formed, and

adding a matrix to the cell lysate to form a complex.

Assignments (8)
CHANGE OF NAME Recorded Feb 24, 2015
From: DEPUY SYNTHES PRODUCTS, LLC
To: DEPUY SYNTHES PRODUCTS, INC.
Reel/Frame 035074/0647 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2014
From: DEPUY ORTHOPAEDICS, INC.
To: DEPUY SPINE, INC.
Reel/Frame 032393/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2014
From: DEPUY SPINE, LLC
To: HAND INNOVATIONS LLC
Reel/Frame 032393/0296 →
CHANGE OF NAME Recorded Mar 10, 2014
From: DEPUY SPINE, INC.
To: DEPUY SPINE, LLC
Reel/Frame 032422/0444 →
CHANGE OF NAME Recorded Mar 10, 2014
From: HAND INNOVATIONS LLC
To: DEPUY SYNTHES PRODUCTS, LLC
Reel/Frame 032422/0493 →
MERGER Recorded Mar 10, 2014
From: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
To: DEPUY ORTHOPAEDICS, INC.
Reel/Frame 032392/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2011
From: ETHICON, INCORPORATED
To: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
Reel/Frame 026291/0076 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2008
From: BROWN, LAURA; HARMON, ALEXANDER M.; GOSIEWSKA, ANNA
To: ETHICON, INCORPORATED
Reel/Frame 021199/0951 →